The application of HER2 to pancreatic cancer treatment
10.3760/cma.j.issn.1007-8118.2013.10.021
- VernacularTitle:人类表皮生长因子受体2在胰腺癌治疗中的应用
- Author:
Guochao ZHAO
;
Yang DENG
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Receptor,epidermal growth factor;
Antibodies,monoclonal;
Tyrosine Kinase Inhibitors;
Biological therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2013;19(10):796-800
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer (PC) is known for its high malignancy and poor prognosis.Furthermore,PC patients have little chance to receive an operation,and chemotherapy is not always an ideal alternative.More effective treatment is necessary because over the last two decades,the morbidity and the mortality of PC has risen continuously.Some new PC treatments involve HER2,a transmembrane protein that has oncological significance.The amplification of its gene or over expression of itself can cause malignant proliferation,suppression of apoptosis,and angiogenesis in PC.Its potential can be seen with HER2 targeted medicines including the clinically used Trastuzumab,but also with bispecific antibody,tyrosine kinase inhibitors,and more.This article will review the application of these new developments.
